Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Bevacizumab in Metastatic Triple-Negative Breast Cancer
NCT00517361Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Aug 2007
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by University of Chicago. Started Aug 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00517361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00517361.